Increasing ACE2 activity in systemic, not tissue, by human recombinant sACE2 administration may provide a new therapeutic target in states of Ang II-dependent hypertension by enhancing Ang II degradation and increasing Ang 1-7 levels [116]. Here, AGT is linked to hypertensive disorder.